Literature DB >> 35113455

Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination.

Zhuofan Li1, Ki-Hye Kim2, Noopur Bhatnagar2, Bo Ryoung Park2, Subbiah Jeeva2, Yu-Jin Jung2, Jannatul Raha2, Sang-Moo Kang2, Xinyuan Chen1.   

Abstract

Pre-pandemic influenza H5N1 vaccine has relatively low immunogenicity and often requires high antigen amounts and two immunizations to induce protective immunity. Incorporation of vaccine adjuvants is promising to stretch vaccine doses during pandemic outbreaks. This study presents a physical radiofrequency (RF) adjuvant (RFA) to conveniently and effectively increase the immunogenicity and efficacy of H5N1 vaccine without modification of vaccine preparation. Physical RFA is based on a brief RF treatment of the skin to induce thermal stress to enhance intradermal vaccine-induced immune responses with minimal local or systemic adverse reactions. We found that physical RFA could significantly increase H5N1 vaccine-induced hemagglutination inhibition antibody titers in murine models. Intradermal H5N1 vaccine in the presence of RFA but not vaccine alone significantly lowered lung viral titers, reduced body weight loss, and improved survival rates after lethal viral challenges. The improved protection in the presence of RFA was correlated with enhanced humoral and cellular immune responses to H5N1 vaccination in both male and female mice, indicating no gender difference of RFA effects in murine models. Our data support further development of the physical RFA to conveniently enhance the efficacy of H5N1 vaccine.
© 2022 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  H5N1; MF59; RFA; physical adjuvant; radiofrequency

Mesh:

Substances:

Year:  2022        PMID: 35113455      PMCID: PMC8928172          DOI: 10.1096/fj.202101703R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  37 in total

1.  Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus.

Authors:  Jae-Min Song; Nico Van Rooijen; Jadranka Bozja; Richard W Compans; Sang-Moo Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Authors:  Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Bo Ryoung Park; Judy Oh; Yu-Na Lee; Min-Chul Kim; Subbiah Jeeva; Sang-Moo Kang
Journal:  Virology       Date:  2020-08-22       Impact factor: 3.616

Review 3.  A year of terror and a century of reflection: perspectives on the great influenza pandemic of 1918-1919.

Authors:  Michaela E Nickol; Jason Kindrachuk
Journal:  BMC Infect Dis       Date:  2019-02-06       Impact factor: 3.090

Review 4.  Human Influenza Virus Infections.

Authors:  Christin Peteranderl; Susanne Herold; Carole Schmoldt
Journal:  Semin Respir Crit Care Med       Date:  2016-08-03       Impact factor: 3.119

5.  Probability of Success and Timelines for the Development of Vaccines for Emerging and Reemerged Viral Infectious Diseases.

Authors:  Amanda MacPherson; Nora Hutchinson; Oliver Schneider; Elisabeth Oliviero; Emma Feldhake; Charlotte Ouimet; Jacky Sheng; Fareed Awan; Catherine Wang; Jesse Papenburg; Nicole E Basta; Jonathan Kimmelman
Journal:  Ann Intern Med       Date:  2020-11-24       Impact factor: 25.391

Review 6.  Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity.

Authors:  Zhuofan Li; Yiwen Zhao; Yibo Li; Xinyuan Chen
Journal:  Vaccines (Basel)       Date:  2021-01-21

7.  Potentiation of Recombinant NP and M1-Induced Cellular Immune Responses and Protection by Physical Radiofrequency Adjuvant.

Authors:  Yibo Li; Zhuofan Li; Yiwen Zhao; Xinyuan Chen
Journal:  Vaccines (Basel)       Date:  2021-11-24

8.  Influenza pandemics of the 20th century.

Authors:  Edwin D Kilbourne
Journal:  Emerg Infect Dis       Date:  2006-01       Impact factor: 6.883

9.  Near-infrared laser adjuvant for influenza vaccine.

Authors:  Satoshi Kashiwagi; Jianping Yuan; Benjamin Forbes; Mathew L Hibert; Eugene L Q Lee; Laura Whicher; Calum Goudie; Yuan Yang; Tao Chen; Beth Edelblute; Brian Collette; Laurel Edington; James Trussler; Jean Nezivar; Pierre Leblanc; Roderick Bronson; Kosuke Tsukada; Makoto Suematsu; Jeffrey Dover; Timothy Brauns; Jeffrey Gelfand; Mark C Poznansky
Journal:  PLoS One       Date:  2013-12-11       Impact factor: 3.240

10.  Augmentation of vaccine-induced humoral and cellular immunity by a physical radiofrequency adjuvant.

Authors:  Yan Cao; Xiaoyue Zhu; Md Nazir Hossen; Prateek Kakar; Yiwen Zhao; Xinyuan Chen
Journal:  Nat Commun       Date:  2018-09-12       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.